All eyes on a hurdle race for a SARS-CoV-2 vaccine.

@article{Gaebler2020AllEO,
  title={All eyes on a hurdle race for a SARS-CoV-2 vaccine.},
  author={C. Gaebler and M. Nussenzweig},
  journal={Nature},
  year={2020},
  volume={586 7830},
  pages={
          501-502
        }
}
economic impact of COVID-19, together with the absence of any clearly effective preventive or therapeutic remedies, has created a massive unmet medical need. Rapid responses by governments, academia and industry have already resulted in the production of more than 180 vaccine candidates (see page 516), 42 of which are being tested in humans at the time of writing. The considerable design flexibility of newer types of vaccine technology gave these candidates a head start in the race. Some of the… Expand

Figures from this paper

COVID-19 Vaccine: Critical Questions with Complicated Answers
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
The Genetic Variant of SARS-CoV-2: would It Matter for Controlling the Devastating Pandemic?
How Will Emerging SARS-CoV-2 Variants Impact Herd Immunity?
Humoral Responses and Serological Assays in SARS-CoV-2 Infections
Persistent Cellular Immunity to SARS-CoV-2 Infection
Persistent cellular immunity to SARS-CoV-2 infection

References

SHOWING 1-10 OF 11 REFERENCES
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
SARS-CoV-2 vaccines in development
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Correlates of Protection Induced by Vaccination
  • S. Plotkin
  • Biology, Medicine
  • Clinical and Vaccine Immunology
  • 2010
...
1
2
...